info@marketresearchfuture.com   📞  +1 (855) 661-4441(US)   📞  +44 1720 412 167(UK)
Certified Global Research Member
Isomar fd.webp Wcrc 57.webp
Key Questions Answered
  • Global Market Outlook
  • In-depth analysis of global and regional trends
  • Analyze and identify the major players in the market, their market share, key developments, etc.
  • To understand the capability of the major players based on products offered, financials, and strategies.
  • Identify disrupting products, companies, and trends.
  • To identify opportunities in the market.
  • Analyze the key challenges in the market.
  • Analyze the regional penetration of players, products, and services in the market.
  • Comparison of major players financial performance.
  • Evaluate strategies adopted by major players.
  • Recommendations
Why Choose Market Research Future?
  • Vigorous research methodologies for specific market.
  • Knowledge partners across the globe
  • Large network of partner consultants.
  • Ever-increasing/ Escalating data base with quarterly monitoring of various markets
  • Trusted by fortune 500 companies/startups/ universities/organizations
  • Large database of 5000+ markets reports.
  • Effective and prompt pre- and post-sales support.

UTI Treatment Market Research Report Information By Drug Class (Quinolones, Aminoglycosides, Β-Lactam, Azoles and Others), By Clinical Indications (Urethritis, Cystitis and Pyelonephritis), By End User (Hospitals and Self-Administered), and By Region (North America, Europe, Asia-Pacific, And Rest Of The World) – Market Forecast Till 2032.


ID: MRFR/Pharma/2268-HCR | 80 Pages | Author: Rahul Gotadki| July 2024

Global UTI Treatment Market Overview


The UTI Treatment Market Size was valued at USD 9.2 billion in 2022 and is projected to grow from USD 9.5 Billion in 2023 to USD 11.9 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 3.7% during the forecast period (2023 - 2032). The market driver for expanding the market is linked to the increased incidence of disorders, including diabetes and obesity in women. In addition, bladder issues and kidney stones are anticipated to fuel market expansion.


UTI Treatment Market


  Source: Secondary Research, Primary Research, MRFR Database and Analyst Review


UTI Treatment Market Trends



  • Growing prevalence and incidence of UTIs to propel market growth


The increased prevalence of UTIs is one of the major factors propelling growth in the market for treatments for urinary tract infections. UTI incidence is rising due to changing lifestyle patterns and interactions between UTIs and other medical diseases. It is anticipated that this will increase the demand for UTI treatment services. Compared to men, women are more likely to get the condition. UTIs are a possibility for about 50% of women worldwide at least once in their lifetime. This has a sizable population and needs a lot of attention. In addition to gender, a number of additional factors contribute to the increased rate of UTIs, including obesity and diabetes. For instance, a 2020 study from the American College of Physicians and the Infectious Diseases Society of America found that UTIs account for about 6 million doctor visits annually in the US. Patients with pre-existing chronic diseases like coronary artery disease (CAD), chronic kidney disease (CKD), and diabetes mellitus (DM) had a higher risk of developing UTIs, according to a 2019 study published in the International Journal of Environmental Research and Public Health. As a result, the high prevalence of UTI leads to a demand for its treatment items, ultimately fueling market expansion. Thus, this factor is driving the market CAGR for UTI treatment.Figure 1: Percentage of urinary tract infection according to gender in different age groups


Percentage of urinary tract infection according to gender in different age groups


Source: Secondary Research, Primary Research, MRFR Database and Analyst Review


Furthermore, hospital-acquired UTI is one of the main examples among the MDR bacteria, which is a serious concern for the infectious disease sector. New kinds of germs, commonly known as superbugs, cause infections resistant to most therapeutic options. The mortality rate of these MDR bacteria ranges from 25% to 60%. Healthcare providers all throughout the world are really concerned about this. For instance, scientists at Queen's University Belfast in Ireland have been researching the causes of superbug resistance to first-line therapy. As a result, there are now more opportunities to comprehend infectious diseases and create new treatments for them. Due to the widespread nature of this issue, significant funding is anticipated for the discovery of effective treatments. The government of Canada, the EU, and a few other wealthy nations have all made efforts to create novel treatments for microbes that are resistant to antibiotics.


However, catheters and other drainage devices are now being used by patients more frequently as a result of the increased prevalence of chronic kidney disorders, including bladder cancer and renal failure. Urinary catheter users are more likely to get complex UTIs.  According to the World Health Organization (WHO), urinary catheter patients run a 5% daily risk of developing bacteriuria, and 40% get nosocomial infections. Catheter-associated urinary tract infection is believed to be caused by a number of causes, including extended catheterization, failure to get systemic antibiotic therapy, bacterial colonization of drainage bags, rapid progression of underlying illnesses, and others. Therefore, the market of UTI treatment will expand as urinary catheter use rises. Thus, it is anticipated that this aspect will accelerate UTI treatment market revenue globally.


UTI Treatment Market Segment Insights


UTI Treatment Drug Class Insights


The Market segments of UTI Treatment, based on drug class, includes quinolones, aminoglycosides, β-lactam, azoles and others. The quinolones segment held the majority share in 2022 in the UTI Treatment Market data. Many medical professionals advise patients to take quinolones to get rid of their infection swiftly. Because of their strong potency, a wide range of activity, excellent absorption, practical formulations, high serum concentrations, and relatively low frequency of adverse effects, quinolones have been chosen as antibiotics for over 50 years.


UTI Treatment Clinical Indications Insights


The UTI Treatment Market segmentation, based on clinical indications, includes urethritis, cystitis and pyelonephritis. The cystitis segment dominated the market growth for UTI treatment in 2022 and is projected to be the faster-growing segment during the forecast period 2022-2030. Pyelonephritis is substantially less frequent than cystitis. The recurrence of cystitis is a significant issue that affects women all over the world. Within six months of the first infection, cystitis can recur in about one-fourth of all women worldwide.


Figure 2: UTI Treatment Market, by Clinical Indications Method, 2022 & 2030 (USD Billion)UTI Treatment Market, by Clinical Indications Method, 2022 & 2030


Source: Secondary Research, Primary Research, MRFR Database and Analyst Review


UTI Treatment End User Insights


The UTI Treatment Market data, based on end user includes hospitals and self-administered. The hospitals segment dominated the market revenue for UTI treatment in 2022 and is projected to be the faster-growing segment during the forecast period, 2022-2030 because more people are getting urinary tract infections and because more people are going to the hospital for testing and treatment of their infections. In addition, patients prefer to visit hospitals since they have a qualified staff.


UTI Treatment Regional Insights


By region, the study provides the market insights for UTI treatment into North America, Europe, Asia-Pacific and Rest of the World. North America UTI treatment market accounted for USD 4.2 billion in 2022 with a share of around 45.80% and is expected to exhibit a significant CAGR growth during the study period. This can be due to several factors, including the high disease burden, significant companies' existence, infrastructure availability, rising healthcare spending, rapid technological breakthroughs, proactive government measures, and increased patient awareness.


Further, the major countries studied in the market report for UTI treatment are: The U.S, Canada, Germany, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.


Figure 3: UTI TREATMENT MARKET SHARE BY REGION 2022 (%)UTI TREATMENT MARKET SHARE BY REGION 2022


Source: Secondary Research, Primary Research, MRFR Database and Analyst Review


Asia Pacific UTI treatment market accounts for the second-largest market share due to the high senior population and rising disease incidence rate. Growing population and the demand for affordable treatment are two variables that greatly impact market expansion. Moreover, China market of UTI treatment held the largest market share, and the India market of UTI treatment was the fastest growing market in the region.


Europe UTI treatment Market is expected to grow at the fastest CAGR from 2022 to 2030. The growth of the urinary tract infection (UTI) in the treatment market will be aided by the presence of many businesses that have made treatment simple. The construction of the health infrastructure is boosting growth overall. New product launches will also result from innovations. In Europe, there are more UTI instances. Further, the UK market of UTI treatment held the largest market share, and the Germany market of UTI treatment was the fastest growing market in the region.


UTI Treatment Key Market Players & Competitive Insights


Major market players are spending a lot of money on R&D to increase their product lines, which will help the market of UTI treatment grow even more. Market participants are also taking a range of strategic initiatives to grow their worldwide footprint, with key market developments such as new product launches, contractual agreements, mergers and acquisitions, increased investments, and collaboration with other organizations. Competitors in the UTI treatment industry must offer cost-effective items to expand and survive in an increasingly competitive and rising market environment.


One of the primary business strategies adopted by manufacturers in the global UTI treatment industry to benefit clients and expand the market sector is to manufacture locally to reduce operating costs. In recent years, UTI treatment industry has provided medicine with some of the most significant benefits. The UTI treatment market major player such as Pfizer, Cipla Inc., GlaxoSmithKline PLC, Novartis AG, Shionogi & Co. Ltd, AstraZeneca and Bayer AG.


With its headquarters in Mumbai, Cipla Limited is a worldwide pharmaceutical corporation. Cipla focuses on creating medications to treat a variety of illnesses, including arthritis, diabetes, depression, cardiovascular disease, respiratory diseases, and many others. In October 2019, Elores was purchased by Cipla from Venus Remedies Ltd. Elores is a medication used to treat infections that can be fatal and is intended to combat antibiotic resistance. The most recent Phase-3 clinical investigation revealed that Elores is superior to meropenem for the treatment of severe urinary tract infections.


Pfizer Inc. is a worldwide pharmaceutical and biotechnology company with its main office in Manhattan, New York City, on 42nd Street. Two German businessmen founded the corporation in 1849 in New York. For the fields of immunology, cancer, cardiology, endocrinology, and neurology, Pfizer develops and produces pharmaceuticals and vaccines. Each of the company's top-selling medicines or goods brings in more than $1 billion in annual sales. In July 2019, Array BioPharma Inc. was fully acquired by Pfizer Inc. When Array BioPharma joined Pfizer, it added a fantastic portfolio, including the authorised combination usage. MEKTOVI and BRAFTOVI.


Key Companies in the market of UTI treatment includes



UTI Treatment Industry Developments


October 2021: Tebipenem HBr tablets were submitted for FDA approval in a new drug application (NDA) by Spero Therapeutics Inc. for the treatment of complex urinary tract infections (cUTI), including pyelonephritis, brought on by susceptible microorganisms.


September 2021: Biapenem was introduced by BDR Pharma, one of the top generic drug makers in India, to treat patients with complex urinary tract infections, lower respiratory infections, and intra-abdominal infections.


UTI Treatment Market Segmentation


UTI Treatment Drug Class Outlook (USD Billion, 2018-2030)



  • Quinolones

  • Aminoglycosides

  • Β-Lactam

  • Azoles

  • Others


UTI Treatment Clinical Indication Outlook (USD Billion, 2018-2030)



  • Urethritis

  • Cystitis

  • Pyelonephritis


UTI Treatment End User Outlook (USD Billion, 2018-2030)



  • Hospitals

  • Self-Administered


UTI Treatment Regional Outlook (USD Billion, 2018-2030)




  • North America

    • US

    • Canada




  • Europe

    • Germany

    • France

    • UK

    • Italy

    • Spain

    • Rest of Europe




  • Asia-Pacific

    • China

    • Japan

    • India

    • Australia

    • South Korea

    • Australia

    • Rest of Asia-Pacific




  • Rest of the World

    • Middle East

    • Africa

    • Latin America



Report Attribute/Metric Details
Market Size 2022 USD 9.2 billion
Market Size 2023 USD 9.5 billion
Market Size 2032 USD 11.9 billion
Compound Annual Growth Rate (CAGR)  3.7% (2023-2032)
Base Year 2022
Market Forecast Period 2023-2032
Historical Data 2018 - 2021
Market Forecast Units Value (USD Billion)
Report Coverage Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends
Segments Covered Drug Class, Clinical Indication, End User and Region
Geographies Covered North America, Europe, Asia Pacific, and Rest of the World
Countries Covered The U.S, Canada, Germany, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil
Key Companies Profiled Pfizer, Cipla Inc., GlaxoSmithKline PLC, Novartis AG, Shionogi & Co. Ltd, AstraZeneca and Bayer AG
Key Market Opportunities ·         Rising incidence of obesity
Key Market Dynamics ·         Female anatomy  ·         Sexual intercourse, diabetes
 

Frequently Asked Questions (FAQ) :

The UTI Treatment Market size was valued at USD 9.2 Billion in 2022.

The UTI Treatment Market is projected to grow at a CAGR of  3.7% during the forecast period, 2023-2032.

North America had the largest share in the global market for UTI treatment.

The key players in the market for UTI treatment are GlaxoSmithKline PLC (UK), Abbott Laboratories (US), Seqirus (UK), Mylan NV (US), AstraZeneca (UK) and Hualan Biological Engineering Inc. (China).

The cystitis dominated the UTI treatment market in 2022.

The hospitals had the largest share in the UTI Treatment Market.

Leading companies partner with us for data-driven Insights
client_1 client_2 client_3 client_4 client_5 client_6 client_7 client_8 client_9 client_10
Kindly complete the form below to receive a free sample of this Report
Please fill in Business Email for Quick Response

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Purchase Option
Single User $ 4,950
Multiuser License $ 5,950
Enterprise User $ 7,250
Compare Licenses
Tailored for You
  • Dedicated Research on any specifics segment or region.
  • Focused Research on specific players in the market.
  • Custom Report based only on your requirements.
  • Flexibility to add or subtract any chapter in the study.
  • Historic data from 2014 and forecasts outlook till 2040.
  • Flexibility of providing data/insights in formats (PDF, PPT, Excel).
  • Provide cross segmentation in applicable scenario/markets.